<DOC>
	<DOC>NCT02079766</DOC>
	<brief_summary>This study will explore the use of 18F-AV-1451 as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.</brief_summary>
	<brief_title>18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Brain Injury, Chronic</mesh_term>
	<criteria>Male subjects consented and currently enrolled in the Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests (DETECT) or the LongTerm Consequences of Repetitive Brain Injury in Athletes study protocols Can tolerate up to two PET imaging sessions Have the ability to provide informed consent for study procedures Claustrophobia Current clinically significant cardiovascular disease or clinically significant abnormalities on screening ECG History of risk factors for Torsades de Pointes or are taking drugs known to cause QTprolongation Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer that the investigator believes would affect study participation or scan results Have had a nonstudy related radiopharmaceutical imaging or treatment within 7 days prior to study PET imaging sessions</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>